Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title: A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo
The Phase 3 CUV105 trial, sponsored by Clinuvel, Inc., evaluates the safety and efficacy of combining SCENESSE (afamelanotide) with NB-UVB phototherapy for generalized vitiligo, focusing on Fitzpatrick skin types IV–VI to address underrepresented populations. The study aims to determine if this combination therapy achieves superior repigmentation outcomes compared to NB-UVB therapy alone.
Key Details:
- Study Type: Interventional (Clinical Trial)
- Phase: Phase 3
- Estimated Enrollment: Not specified
- Age Range: 12 years and older
- Duration: Approximately 308 days, including treatment and follow-up periods
Eligibility Criteria:
Inclusion:
- Individuals aged 12 years or older
- Confirmed diagnosis of generalized vitiligo with a Vitiligo Area Scoring Index (VASI) of ≥0.3 on the body and face
Exclusion:
- Pregnant or lactating females
- Females of childbearing potential not using adequate contraceptive measures
- History of melanoma or lentigo maligna
- Presence of skin cancer lesions
- Severe liver disease or impairment
- Allergy to afamelanotide or its implant material
Additional Information: Participants will be randomly assigned to receive either NB-UVB light therapy alone or in combination with SCENESSE implants. The study will assess the percentage of patients achieving significant repigmentation, as measured by the VASI scoring system, over the course of the trial. For more details or to inquire about participation, please visit the official trial page.
Start date: 2023-10-11
Completion date: 2025-06-01
Contact: Head of Clinical Operations
Tel.: +441372860765
Email: clinicaltrials@clinuvel.com
Link: https://clinicaltrials.gov/study/NCT06109649
FAQOther Questions
- Shall I take vitamin D for my vitiligo?
Vitamin D plays a central role in the prevention of different inflammatory and chronic diseases. Consuming 1,000–4,000 IU (25–100 mcg) of vitamin D3 daily should be ideal for mo...
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.